Phase 2 Interstitial Lung Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be 18 years old or older at the time you agree to take part.
• You must have early-stage non-small cell lung cancer (Stage I or II), confirmed by a tissue sample where possible, or by scans and specialist agreement if a biopsy is too risky.
• You must have been diagnosed with a lung scarring/inflammation condition called interstitial lung disease (ILD), either by a lung specialist, by scan results with a specific breathing test result, or because it developed from a connective tissue disease (such as rheumatoid arthritis, lupus, or similar conditions).
• You must be well enough to carry out some daily activities (your doctor will assess this using a standard scale from 0 to 3).
• If you are a woman who could become pregnant, you must either be confirmed post-menopausal (no periods for 12 months or more without another medical reason) or have a negative pregnancy test before joining.
• You must be expected to live for at least 6 months.

Who may not be able to join:

• You have had radiation treatment to the chest area before.
• You have had a surgical procedure to remove an entire lung (pneumonectomy).
• You have had a major operation (such as brain, chest, abdominal, or pelvic surgery) within the last 28 days.
• You have a serious other illness that could prevent you from completing the radiation treatment or study procedures.
• You have a known allergy or bad reaction to any of the study medications or their ingredients.
• Your ILD has recently got much worse and required a hospital stay in the last 30 days.
• You have poorly controlled heart rhythm problems that are not responding to treatment, or you have a pacemaker.
• You are pregnant, breastfeeding, or able to have children and are not willing to use effective non-estrogen-based contraception (such as a condom plus a diaphragm, IUD, or certain other methods) from the start of the study until 30 days after the last dose of study medication.
• You are currently taking or plan to take other experimental cancer treatments, chemotherapy, immunotherapy, or certain medications that affect the immune system (such as rituximab, tocilizumab, or similar drugs) at the same time as the study drug.

Important: Always verify eligibility with the trial site directly before applying.